Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway

Figure 2

Brusatol inhibited the Nrf2 pathway and increase ROS accumulation in pancreatic cancer cells. (a) 0.5 μM brusatol was utilized to treat the expression of Nrf2 in PATU-8988 cells for the indicated time points. (b) 0.5 μM brusatol lowered the protein levels of Nrf2 and its downstream genes after 8-hour treatments. (c) 0.5 μM brusatol reduced the mRNA level of Nrf2 target genes after 8-hour treatments. (d) Cells were treated with 0.5 μM brusatol for 24 hours, and intracellular ROS generation was analyzed by DCFH-DA using a fluorescence microscope (magnification, 100x). (e) Cells were treated with 0.5 μM brusatol for 24 hours, and intracellular ROS generation was analyzed by DCFH-DA using flow cytometry. (f) The fluorescence intensity of DCF described in (e) was quantitated. The data showed representatives of at least three independent experiments. compared with the control group.

(a)

(b)

(c)

(d)

(e)

(f)